MedTrace Logo

Multipeptide Vaccine for Advanced Breast Cancer

NCT00573495 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2016-09-29

No results posted yet for this study

Summary

This is a study on how to activate the immune system with a vaccine. The vaccine is made up of two proteins found in breast cancer: telomerase and survivin. The vaccine is given in combination with other drugs that may also have an effect on the immune system and attack the cancer.

The goals of the study are:

1. to test the safety of the combination of agents
2. to find out what effects the treatment has on advanced breast cancer

Conditions

  • Breast Neoplasm
  • Breast Cancer
  • Cancer of the Breast
  • Carcinoma, Ductal

Interventions

BIOLOGICAL

hTERT/Survivin Multi-Peptide Vaccine

100 mcg subcutaneous every 2 weeks four times, then monthly up to 28 vaccinations

Sponsors & Collaborators

Principal Investigators

  • Kevin Fox, MD · University of Pennsylvania

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2011-07-31
Completion
2013-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00573495 on ClinicalTrials.gov